Identification of circulating miRNA biomarkers based on global quantitative real-time PCR profiling

Table 2 Summary of circulating miRNA biomarkers identified through qRT-PCR profiling

	Step 1			Step 2	Step 3	Step 4
Disease	No. Pa/Nor	Type	Kit	Method	Normalizer	No. Pa/Nor	Marker	Function	Statistical analysis	References
ovarian cancer	9/4	S	TR	AB	U44 U48	19/11	miR-21 miR-92 miR-93	Severity	Mann-Whitney	[27]
prostate cancer	21/ N/A	S	TR	AB	cel-miR-39 cel-miR-54 cel-miR-238	113/ N/A	miR-375 miR-141	Severity Tissue	Limma analysis ANOVA	[28]
colorectal cancer	5/5	P	Tz	SBI	U6	115/70	miR-17 -3p miR-92	Severity Tissue Prognosis	Mann-Whitney Wilcoxon the χ² test Kruskal-Wallis ROC	[21]
HBV infected	51/12	S	mir	AB	U6	51/12	miR-122	Severity	Mann-Whitney	[29]
Crohn disease	46/32	S	mir	AB	miR-302a miR-372 miR-302d cel-miR-54 cel-miR-238	46/32	11 miRNAs*	Severity Prognosis	Mann-Whitney Hierarchical- cluster ROC	[30]
liver disease	5/2	S	mir	AB	U6	112/24	miR-885-5p	Comparison	Mann-Whitney Kruskal-Wallis ROC	[24]

HBV: hepatitis B virus; Pa: patients; Nor: normal; N/A: not available; S: serum; P: plasma; TR: Tri-Reagent BD (Molecular Research Center or Sigma); Tz: Trizol LS reagent (Invitrogen); mir: mirVana™ miRNA isolation kit (Ambion); AB: Megaplex™ Pools (Applied Biosystems); SBI: QuantiMir™ (System Biosciences); Severity: correlation of miRNAs expression level with disease severity; Prognosis: correlation of miRNAs expression level and the treatment of disease; Tissue: correlation of miRNAs expression level in serum with that in tissue; Comparison: comparison between newly identified miRNA biomarkers and conventional biomarkers; ROC: Receiver operating characteristic curve; ANOVA: Analysis of variance.
*: miR-16, miR-195, miR-106a, miR-20a, miR-30e, miR-140, miR-484, miR-93, miR-192, miR-21, let-7b.

ISSN: 2049-1891